Table 1.
Demographics of subjects from the EMIF-AD MBD study
| Variable | Subjects included in Oxford sample set | Subjects included in Cardiff sample set | ||||
| Normal amyloid status | Abnormal amyloid status | p | Low amyloid status | High amyloid status | p | |
| N | 457 | 543 | / | 460 | 406 | / |
| Aβ Z-score | 0.49±0.62 | –1.35±0.48 | <0.001* | 0.45±0.62 | –1.36±0.51 | <0.001* |
| Age (y) | 66.52±8.71 | 69.81±8.12 | <0.001* | 66.61±8.25 | 70.47±8.22 | <0.001* |
| Female gender N (%) | 223 (49) | 301 (55) | <0.05* | 253 (55) | 226 (56) | 0.844 |
| CTL N (%) | 289 (63) | 119 (22) | / | 272 (59) | 88 (22) | / |
| MCI N (%) | 147 (32) | 253 (47) | / | 179 (39) | 234 (58) | / |
| AD N (%) | 21 (5) | 171 (31) | / | 9 (2) | 84 (21) | / |
| APOE genotype ɛ4+ N (%) | 147 (32) | 349 (64) | <0.001* | 134 (29) | 246 (61) | <0.001* |
| MMSE | 27.93±2.49 | 25.11±4.29 | <0.001* | 28.09±2.23 | 25.41±4.26 | <0.001* |
MCI, mild cognitive impairment; AD, Alzheimer’s disease, APOE, apolipoprotein E; CTL, cognitively healthy control; MMSE, Mini-Mental State Examination. Mean±standard deviation. *Statistically significant by Mann-Whitney U, p < 0.05.